Mutations and Phenotypes of Unclassifiable Inherited Bone Marrow Failure Syndromes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

250 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-10

Study Completion Date

2028-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Inherited bone marrow failure syndromes (IBMFSs) are a diverse collection of genetic illnesses characterized by various degrees of peripheral cytopenias due to defective single-lineage or multi-lineage hematopoiesis, it can manifest itself at birth or later in life.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Investigation of the Genetics of Hematologic Diseases

NCT02720679

Leukocyte Disorder Bone Marrow Failure Syndromes Erythrocyte Disorder +10 more

RECRUITING

Use Massive Parallel Sequencing and Exome Capture Technology to Sequence the Exome of Fanconi Anemia Children and Their Patents

NCT01995305

Fanconi Anemia Autosomal or Sex Linked Recessive Genetic Disease Bone Marrow Hematopoiesis Failure, Multiple Congenital Abnormalities, and Susceptibility to Neoplastic Diseases. +1 more

AVAILABLE

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NCT06923670

Polycythemia Vera Essential Thrombocythaemia Myelofibrosis

NOT_YET_RECRUITING NA

Evaluation of Optical Genome Mapping in Phi Negative Myeloproliferative Neoplasia in the Detection of Acquired Cytogenetic Abnormalities

NCT05714592

Myeloproliferative Neoplasm Optical Genome Mapping Cytogenetics +2 more

UNKNOWN NA

Familial Myeloproliferative Disorders

NCT00666289

Polycythemia Vera Essential Thrombocythemia Idiopathic Myelofibrosis

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Studying the genetic etiology underlying unclassifiable IBMFSs with bone fragility fractures should be useful for clarifying the undiagnosed pathophysiological mechanisms and other accessory factors to improve the diagnosis, follow-up, prognosis, and management of these patients as well as prevent future complications.

Moreover, early diagnosis of risk factors of unusual presentations of IBMFSs will be a useful tool for better treatment strategy.

In addition, along with typical IBMFSs, novel clinical entities must be included in an overall molecular portrait of IBMF disorders. As a result, comprehensive genetic analysis will be effective in establishing an accurate genetic diagnosis at medical evaluation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inherited BMF Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

The whole-exome sequencing

Exome sequencing will be performed at the Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan and will be analyzed at Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Japan.

Intervention Type GENETIC

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Radiologic assessment Histopathological studies of BM biopsies • Chromosomal fragility testing

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed a two-generational family with IBMFSs presented with signs and symptoms of bone fragility fractures and admitted or treated in Hematology Division at Internal Medicine Departments of various university hospitals will be screened for enrollment in this study.
* The investigators will invite the entire family for testing for IBMFSs mutations, and three additional family members consented to participate in this study.

Exclusion Criteria

* • Patients will be diagnosed with paroxysmal nocturnal hemoglobinuria

* Patients will be diagnosed with de novo myelodysplastic syndrome
* IBMFSs-patients will refuse to consent to this study.
* Serologic evidence of recent virus infection as hepatitis A (HAV), HBV, HCV, HEV, cytomegalovirus (CMV), Epstein-Barr virus (EBV), or positive test for HIV.
* IBMFSs patients with severe systemic diseases (such as cardiovascular, renal, and hepatic disease) or surgical/medical conditions that might interfere with follow-up instructions.
* IBMFs patients with psychiatric disorders or a history of drug abuse,

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes